SCHEMBL1891598

SCHEMBL1891598

CCCc1c(OCCCOc2ccc(-c3cscn3)c(OC)c2CC2CC2)ccc2c1OC(C(=O)O)CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 20/20 1.00
LTB4R2 Q9NPC1 12/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31539110 1.00 LTB4R (1.00) LTB4RLTB4R2
SCHEMBL8990430 0.95 LTB4R (1.00) LTB4RLTB4R2
SCHEMBL8990429 0.91 LTB4R (1.00) LTB4RLTB4R2
SCHEMBL9198076 0.90 LTB4R (0.81) LTB4RLTB4R2
SCHEMBL9198565 0.89 LTB4R (0.87) LTB4RLTB4R2
SCHEMBL9378602 0.87 LTB4R (0.77) LTB4RLTB4R2
SCHEMBL9376755 0.87 LTB4R (0.77) LTB4RLTB4R2
SCHEMBL9196119 0.85 LTB4R (0.80) LTB4RLTB4R2
SCHEMBL9192878 0.85 LTB4R (0.88) LTB4RLTB4R2
SCHEMBL8990416 0.84 LTB4R (0.78) LTB4RLTB4R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190216790-A1 Methods for Treating Pruritis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-07-18 US claimed
WO-2018071687-A1 METHODS OF TREATING PRURITIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-04-19 WO claimed
US-20170333516-A1 PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION JUNTENDO EDUCATIONAL FOUNDATION (JP) 2017-11-23 US claimed
WO-2001034199-A2 ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER ELI LILLY AND COMPANY (US) 2001-05-17 WO claimed
EP-0527922-B1 ALKOXY-SUBSTITUTED DIHYDROBENZOPYRAN-2-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF SEARLE & CO (US) 1995-03-08 EP claimed
EP-0527922-A1 ALKOXY-SUBSTITUTED DIHYDROBENZOPYRAN-2-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF. SEARLE & CO (US) 1993-02-24 EP claimed
US-5073562-A Antiinflammatory agents; leukotriene by antagonists G. D. SEARLE & CO. (US) 1991-12-17 US claimed
WO-1991017160-A1 ALKOXY-SUBSTITUTED DIHYDROBENZOPYRAN-2-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF G.D. SEARLE & CO. (US) 1991-11-14 WO claimed
US-10849954-B2 Preventive or therapeutic agent for age-related macular degeneration JUNTENDO EDUCATIONAL FOUNDATION (JP) 2020-12-01 US disclosed
US-20190216790-A1 Methods for Treating Pruritis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-07-18 US disclosed
US-20170333516-A1 PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION JUNTENDO EDUCATIONAL FOUNDATION (JP) 2017-11-23 US disclosed
EP-2471954-B1 Genetic susceptibility variants associated with cardiovascular disease DECODE GENETICS EHF (IS) 2016-08-24 EP disclosed
US-20160166508-A1 Method and Composition for Treating Inflammatory Disorders MEDA AB (SE) 2016-06-16 US disclosed
US-20160166508-A1 Method and Composition for Treating Inflammatory Disorders MEDA AB (SE) 2016-06-16 US disclosed
WO-1995032201-A1 ALKOXY-SUBSTITUTED DIHYDROBENZOPYRAN-2-SULFONIMIDES DERIVATIVES, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B4 ANTAGONISTS G.D. SEARLE & CO. (US) 1995-11-30 WO disclosed
EP-0527922-B1 ALKOXY-SUBSTITUTED DIHYDROBENZOPYRAN-2-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF SEARLE & CO (US) 1995-03-08 EP disclosed
US-5212198-A Antiinflammatory agents G. D. SEARLE & CO. (US) 1993-05-18 US disclosed
US-5192782-A Leukotriene antagonists, antiinflammatory agents G. D. SEARLE & CO. (US) 1993-03-09 US disclosed
EP-0527922-A1 ALKOXY-SUBSTITUTED DIHYDROBENZOPYRAN-2-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF. SEARLE & CO (US) 1993-02-24 EP disclosed
WO-1991017160-A1 ALKOXY-SUBSTITUTED DIHYDROBENZOPYRAN-2-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF G.D. SEARLE & CO. (US) 1991-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10849954-B2 Preventive or therapeutic agent for age-related macular degeneration LTB4R, LTA4H, LTB4R2 LTB4R 1/4885LTB4R2 3/4885
US-20190216790-A1 Methods for Treating Pruritis ITCH, CYSLTR2, CYSLTR1 LTB4R 8/4885LTB4R2 4/4885
US-20170333516-A1 PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION LTB4R, LTA4H, LTB4R2 LTB4R 1/4885LTB4R2 3/4885
US-20160166508-A1 Method and Composition for Treating Inflammatory Disorders LIPA, HRH2, HRH1 LTB4R 8/4885LTB4R2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.